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Abstract: Gluten elimination may represent an effective treatment strategy for mood disorders in
individuals with gluten-related disorders. However, the directionality of the relationship remains
unclear. We performed a systematic review of prospective studies for effects of gluten on mood
symptoms in patients with or without gluten-related disorders. Six electronic databases (CINAHL,
PsycINFO, Medline, Web of Science, Scopus and Cochrane Library) were searched, from inception
to 8 August 2018, for prospective studies published in English. Meta-analyses with random-effects
were performed. Three randomised-controlled trials and 10 longitudinal studies comprising 1139
participants fit the inclusion criteria. A gluten-free diet (GFD) significantly improved pooled
depressive symptom scores in GFD-treated patients (Standardised Mean Difference (SMD) −0.37,
95% confidence interval (CI) −0.55 to −0.20; p < 0.0001), with no difference in mean scores between
patients and healthy controls after one year (SMD 0.01, 95% CI −0.18 to 0.20, p = 0.94). There was a
tendency towards worsening symptoms for non-coeliac gluten sensitive patients during a blinded
gluten challenge vs. placebo (SMD 0.21, 95% CI −0.58 to 0.15; p = 0.25). Our review supports the
association between mood disorders and gluten intake in susceptible individuals. The effects of a
GFD on mood in subjects without gluten-related disorders should be considered in future research.
Keywords: gluten-related disorders; gluten-free diet; coeliac disease; non-coeliac gluten sensitivity;
irritable bowel syndrome; mood disorders; affective disorders; depression; major depressive disorder;
mental health; nutrition
1. Introduction
Mood disorders are a global healthcare burden, with 300 million people now suffering from
depression worldwide [1]. In 2015, the World Health Organisation (WHO) estimated that 4.4% of the
global population were suffering from clinical depression—a 18.4% increase in prevalence since 2005.
On top of this, around 61 million antidepressants are prescribed in a single year in the UK alone [2],
while depressive disorders were ranked as the largest contributor to global non-fatal health loss, as
well as increased suicide risk [3].
Wheat products are now the main source of carbohydrate in the Western diet and contain
high amounts of the protein, gluten. In recent years, reports of gastrointestinal and extra-intestinal
symptoms, due to gluten-containing foods have been on the increase [4]. Coeliac disease (CD)
is characterised by intestinal mucosal damage due to an immune response to gluten peptides,
with clinical improvement after following a gluten-free diet (GFD) [5]. This involves the elimination
of gluten-containing foods from the diet, such as wheat, rye and barley products. CD affects about
1% of the UK population [6] and its global prevalence is on the rise [7]. Moreover, around 10%
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of CD patients are affected by psychiatric disorders [8], with a higher proportion of CD patients
exhibiting depression compared to the general population [9]. However, CD can manifest in a variety
of ways, with symptomatically atypical and silent patient subgroups [10], and hence is thought to
be underdiagnosed [5]. Therefore, it is a possibility that CD may be misdiagnosed, as depression for
example, due to a lack of classical symptoms.
A growing body of evidence suggests that mood symptoms are associated with a spectrum of
gluten-related disorders [9,11,12]. Reports of health improvements after following a GFD in the absence
of CD has led to non-coeliac gluten sensitivity (NCGS) becoming increasingly recognised as its own
clinical entity [13], with evidence indicating a higher prevalence than CD [14]. In contrast to CD, specific
serological markers for NCGS are lacking; only some patients exhibit increased antibodies to gluten
peptides and no mucosal damage is generally observed [15]. Nonetheless, in 1956 it was suggested
that gluten may be associated with mood and psychiatric symptoms in a case series of subjects without
CD [16]. More recently, mood symptoms are frequently reported as a result of wheat ingestion [17]
with ‘low mood’ being a common motivation for gluten avoidance [18] in the absence of both CD
and wheat allergy. Furthermore, recent clinical studies have found raised gluten-related antibodies
in patients with bipolar, major depressive disorder, and schizophrenia [19–21], while episodes of
acute mania may be associated with increased serum levels of antibodies against gliadin [22]. Hence,
there is mounting evidence for a, potentially bidirectional, relationship between gluten sensitivity and
psychiatric disorders.
Numerous theories regarding the aetiology of mood symptoms in those with gluten-related
disorders exist. One theory suggests that an immune response to gluten may lead to depressive
symptoms [23]. Further evidence suggests social exclusion could lead to depression in CD [6] while
another study relates mood symptoms to adjusting to the chronic nature of a physical disease in
general [24]. Contrary to this, Roos et al. found no relationship between gastrointestinal symptoms
and psychological well-being in CD [25], although antidepressants have interestingly been found to
reduce abdominal pain in irritable bowel syndrome (IBS) [26]. Conversely, nutritional deficiencies
may be a causative factor for reduced mood; for instance, B-vitamin supplementation was found to
significantly improve depression in adults with longstanding CD on a GFD [27]. Finally, the ingestion
of FODMAPs (Fermentable Oligo-, Di-, Mono-saccharides And Polyols—short chain carbohydrates
also present in wheat, rye and barley, as well as beans, pulses and certain vegetables), have also
been suggested to increase both physical and psychological symptoms in those thought to be gluten
sensitive [28,29]. Hence, there appears to be a complex and multifactorial relationship between mood
and gluten-related disorders.
Regardless, a GFD has been shown to improve mental health in susceptible individuals. Significant
improvements in mood disorders and psychological well-being have been recognised in patients with
CD [30–32], IBS [33] and NCGS [34] following a GFD, although the magnitude of improvement is found
to be dependent on good dietary adherence [11,35]. Moreover, anti-gliadin IgG antibodies disappeared
in NCGS patients [34] and markers of systemic inflammation were reduced in IBS patients [36], as well
as healthy mice [37] following initiation of a GFD. Hence, a GFD may reduce inflammation and
improve mood, although a relationship between these outcomes remains theoretical.
Whilst the GFD for autism spectrum disorders has been well reviewed [38,39], other reviews
of psychiatric and mood disorders in relation to gluten have focussed on CD and epidemiological,
rather than interventional, evidence [12,40]. Meanwhile, a review on extra-intestinal symptoms in
NCGS [41] included only one study considering psychiatric outcomes [42]. However, a search of
registered protocols did not reveal that any systematic reviews on gluten and mood are planned or
currently in progress. Therefore, we conducted a systematic review of prospective studies with a
gluten challenge or GFD intervention on the prevalence and/or severity of mood symptoms in patients
with or without gluten-related disorders. Our study was underpinned by the following objectives: To
establish whether a relationship exists between mood and gluten; to explore the outcomes of severity
mood symptoms and the prevalence of mood disorders; to assess the impact of the level of adherence
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to a GFD on the severity of mood symptoms; to highlight gaps in the research literature; and to
determine implications for practice in terms of implementing a GFD in those with gluten-related and
mood disorders.
2. Materials and Methods
2.1. Eligibility Criteria
The eligibility criteria for inclusion of studies into our systematic review consisted of the following:
1. All studies evaluating the effect of gluten ingestion or elimination on the presence or severity of
depressive symptoms and other mood disorders, with any gluten-related intervention for any
length of time.
2. As evidence suggests a correlation between mood and level of adherence to a GFD [35,43,44],
dietary adherence must be defined using a validated measure and either specify good adherence
or report data for adherent and non-adherent participants separately.
3. All prospective intervention studies—randomised, non-randomised, longitudinal—which
investigated the change in the severity of mood symptoms as a primary or secondary outcome
using a validated questionnaire. We excluded retrospective and cross-sectional studies, as we
aimed to investigate the relationship between mood and gluten over a specified amount of time
while measuring adherence.
4. Published studies in English.
Further to this, we defined the following eligibility criteria for inclusion of study data into
meta-analysis:
1. Data must be reported as means and standard deviations (SDs), or these values must be
calculatable or estimable using the available data by methods outlined in the Cochrane
Handbook [45].
2. Each study should report a different sample; for different studies utilising the same sample,
as part of a follow-up study or ad-hoc analysis for example, only data from the most relevant
study or the study reporting the largest sample were included.
3. For comparisons between patients and healthy controls, control and patient groups must be
demographically matched by age and gender.
2.2. Search Strategy and Selection Criteria
The scientific databases CINAHL, PsycINFO, Medline, Web of Science, Scopus and the Cochrane
Library were searched using the strategies outlined in Tables S1–S6 in Supplementary File 1. These were
designed using keywords, Medical Subject Heading (MeSH) terms and free text words, such as
gluten-free diet and depression, combined using Boolean operators. The strategies were piloted for
each database and three authors (E.B., J.B. and L.F.) reviewed and amended the search strategy before
E.B. commenced the final search. To ensure all relevant studies were captured, two authors (E.B. and
J.B.) independently screened and selected the studies. In cases of disagreement, a third author (L.F.)
was consulted for the final decision. Reference lists of relevant studies were also searched.
2.3. Data Extraction and Quality Assessment
One reviewer (E.B.) extracted the data according to a data extraction form developed to
collect information regarding study design, population, intervention, controls and outcomes.
The data extraction form included information on authors, country, recruitment methods, number
of participants, methods of measuring adherence, level of dietary adherence, commercial funding
and/or conflicts of interest, study/intervention duration and analysis strategy (ITT—intention-to-treat;
PP—per-protocol). Further data was extracted in order to assess risk of bias (ROB) according to tools
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developed by the Cochrane Collaboration; Cochrane’s ROB 2.0 (University of Bristol, Bristol, UK) [46]
was used for randomised controlled trials (RCTs) and the Risk Of Bias In Non-randomized Studies of
Interventions (ROBINS-I) tool (University of Bristol, Bristol, UK) [47] for all types of non-randomised
studies. The bias domains included in ROBINS-I overlap with the Cochrane ROB 2.0 tool, but instead
of assessing the randomisation process, include the additional domains: Confounding, selection of
participants into the study and classification at intervention. Specific criteria for assessing the risk of
bias in each of the domains in the context of our review are described in Table S7 in Supplementary
File 2.
2.4. Statistical Analysis
We performed all meta-analyses with Review Manager (RevMan) 5.3 (The Nordic Cochrane
Centre, Copenhagen, Denmark, 2014). Outcomes are based on random-effects models using mean
differences. Results from the analysis are presented as mean differences along with the 95% confidence
intervals. Statistical significance was set at 0.05 for two-sided p-values. Data was synthesised by
meta-analysis when there was a consistent comparison in two or more studies measuring depressive
outcomes. Where possible, only depressive outcome data from questionnaires not biased towards
physical illness, with no questions related to gastrointestinal health and eating habits, were synthesised
in meta-analysis; data from studies using biased questionnaires containing these types of questions
were reported separately. For continuous data, scores from depression scales were reported as
means and the standardised mean difference (SMD) was used as a summary statistic. The means
of psychometric scales that increased with severity of depression were multiplied by −1 to ensure
that all the scales point in the same direction. Dichotomous data were presented as the percentage
of patients who were depressed with a score above a specified cut-point, which we reported only
when the cut-point score used in the study was based on a validated rather than arbitrary figure.
Risk difference (RD) was used to report the results as this is a measure of absolute effect and more
intuitive to interpret [45], especially for change of scores from baseline. Funnel plots were used to
evaluate publication bias. All forest plots were stratified according to risk of detection bias. We have
highlighted this domain as the key risk of bias domain for our study due to our outcome of interest
being a subjective measurement. We used the Grades of Recommendation, Assessment, Development
and Evaluation Working Group (GRADE Working Group) system [48,49] for grading the quality
of evidence for each outcome according to study design, consistency, directness, imprecision and
reporting bias. We used GRADEpro GTD to build the Summary of Findings (SoF) and GRADE profile
tables [50].
2.5. Heterogeneity and Sensitivity Analyses
Heterogeneity between studies was interpreted according to general guidance [51], which suggest
that I2 values of 25%, 50%, and 75% may indicate low, medium and high heterogeneity, respectively,
while a value of 0% indicates no observed heterogeneity. To address the most important sources of
heterogeneity, we performed planned subgroup analyses considering the effect of CD (CD vs. non-CD
participants), gastrointestinal symptoms (symptomatic vs. asymptomatic), and the presence of the
CD-associated HLA-DQ2/8 genotype (positive vs. negative) on depressive outcome measures. We
also retrospectively performed a subgroup analysis into population sample country of origin after
extracting and analysing the data in order to further investigate heterogeneity. The effect of dietary
adherence (compliant vs. noncompliant participants) was analysed as a separate comparison so as to
include data from Nachman et al. (2010). Sensitivity analyses were performed for: Study searching,
by including abstracts whose results could not be confirmed in subsequent publications; data selection,
by excluding results from studies utilising an ITT approach; study methods, by analysing only studies
with an average intervention time of one year; study quality, by excluding studies at a high risk of bias
in key domain(s); and analysis methods by changing random-effects (RE) for fixed-effects (FE) and
risk differences (RD) for risk ratios (RR) and odds ratios (OR).
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2.6. Missing Data
All studies reporting the necessary outcome data as mean values with SDs were included
in meta-analysis. If the necessary data was not reported in the correct format for meta-analysis,
the corresponding author of the relevant study was contacted via email to request the required data.
If no reply was received, a reminder email was sent three weeks after the initial request and other study
authors were contacted if emails could be retrieved. As a final resort, and if possible, means and SDs
were calculated from the available information (as long as the data were determined to be normally
distributed) according to the methods outlined in Chapter 7 of the Cochrane Handbook version
5.1.0 [45]. Some scores were derived from graphs by optical plot reading using WebPlotDigitizer
(Version 4.1, Ankit Rohatgi, Austin, TX, USA) [52].
3. Results
3.1. Literature Search
The final literature search for all databases was conducted on 8 August 2018 by E.B. These searches
identified 236 papers, three additional citations were identified by a recursive bibliography
search [34,53,54], one study was referred by an expert in the field [55] and one study was already
known by the authors [29]. After excluding records based on duplicate data, title or abstract, fifty-one
were fully reviewed. Finally, 13 studies met the inclusion criteria (Figure 1). The characteristics of
these included studies are summarised in Table 1. A summary of reasons for the studies excluded by
full-text screening are provided in Table S8 in Supplementary File 3.
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separately. 
There were differences in the questionnaires utilised to measure the severity of depression 
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one the Hamilton Depression Rating Scale (HDRS) [59]. However, one of these studies reported some 
3.2. Characteristics of the Included Studies
Of the 13 studies, three were RCTs [42,53,56]. Study participants were subjects with self-reported
NCGS with [42] and without [56] diagnosed IBS, and asymptomatic EmA-positive subjects [53]. Each of
these studies excluded CD either by previous diagnosis [53] or study screening [42,56]. The remaining
10 studies were single arm before-after studies; one of these was a time-interrupted study and one
was a follow-up study. Of these, two reported on the same group of participants; Nachman et al.
(2009) reported the initial study period from baseline to one year at intervals of three months for all
participants, while Nachman et al. (2010) reported baseline, one-year and four-year follow-up results
for a subset of the same participants (n = 53) who continued to follow a GFD for the full four years.
Although using the same sample, both studies were included as they elucidate the short and long-term
effects of a GFD on depressive symptoms. Nevertheless, results from these studies were not pooled in
meta-analysis as they report on the same participants, and hence were analysed separately.
There were differences in the questionnaires utilised to measure the severity of depression
between the included studies. Three studies used questionnaires containing questions related to
gastrointestinal health and eating habits; two used the Beck Depression Inventory (BDI) [57,58], and
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one the Hamilton Depression Rating Scale (HDRS) [59]. However, one of these studies reported some
data from a sub-analysis removing these questions [58]. Conversely, nine studies used questionnaires
containing no such questions; four used the Psychological General Well-Being Index (PGWB) [53,60–62],
one the Hospital Anxiety and Depression Scale (HADS) [63], one the Crown-Crisp Experiential Index
(CCEI) [64], one the Children’s Depression Inventory (CDI) [11] and one the State-Trait Personality
Inventory (STPI) [42], while one further study [65] used a modified version of the Zung Self-Rating
Depression Scale (SDS) with such questions removed. Finally, one study simply asked participants to
grade depression as present or absent on each day [56].
3.3. Quality Assessment
Of the RCTs, one study was found to have a low risk of bias and two were found to have a high
risk of bias. Of the non-randomised studies, three were found to have a moderate risk of bias while the
remaining seven were found to have a serious risk of bias. Graphical representations of the summary
of risk of bias for individual studies and across all studies are given in Figure 2, and the analysis of
each domain is detailed in Supplementary File 4.Nutrients 2018, 10, x FOR PEER REVIEW  11 of 25 
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Table 1. Characteristics of included studies.
Author (Year) Country ofOrigin/Study Design Participants Healthy Controls Interventions Outcomes
Method of Measuring
Adherence * Notes
Addolorato et al.
(2001) [65]
Italy
Single centre
BA comparison
35 newly diagnosed
classical CD patients
59 HC recruited from
hospital staff members GFD for 1 y
Changes in depression score BA a
GFD (M-SDS)
Changes in no. patients positive
for depression BA a GFD (M-SDS
score > 49)
1—validated
2—family member interview
3—AGA, EmA
4—biopsy at 6–8 mo
Aziz et al.
(2016) [63]
UK
Single centre
BA comparison
41 IBS-D patients; 20
HLA-DQ2/8+ and 21
HLA-DQ2/8−
NC
GFD for 6 wk; FU at 18 mo
for those who continued
on GFD
Changes in HADS before and
after a GFD
Difference between
HLA-DQ2/8+/− groups
1—validated
(“Patients scoring 0 or 1 do
not follow a strict GFD.
Patients scoring 2 follow a
GFD but with errors
necessitating correction.
Finally, patients scoring three
or four follow a strict GFD.”)
Educational grant from Dr.
Schär (a gluten-free food
manufacturer) to
undertake
investigator-conceived
and -led research on
gluten sensitivity
Bella et al.
(2015) [59]
Italy
Single centre
BA comparison
(FU study from
Pennisi et al. (2014))
13 CD patients NC GFD for 16 mo
Changes in depression score BA a
GFD (HDRS)
Changes in no. patients positive
for depression (dysthymia) BA a
GFD (SCID-I)
1—validated
3—EmA, tTG
Collin et al.
(2008) [64]
Finland
Single centre
BA comparison
20 biopsy-proven CD
patients
HCs not recruited from
same community
(female students/male
workers)
GFD for 1 y
Changes in depression score BA a
GFD (sub-score of
CCEI/Middlesex Hospital
Questionnaire)
3—EmA
4—Vh/CrD
Di Sabatino et al.
(2015) [56]
Italy
Multicentre
DB, PC, CO RCT
59 patients suspected of
having NCGS (CD and
WA excluded)
NA
2 arms; GFD (1 wk baseline
period) followed by 1 wk:
(a) 4.375 g/day gluten
(b) rice starch placebo
with 1 wk wash-out periods
inbetween
Difference in mean daily
depression scores (unvalidated
questionnaire) between gluten
and placebo groups
1—validated
6—unused capsules counted
Kurppa et al.
(2010) [60]
Finland
Single centre
Cohort
73 EmA-positive adults;
27 mild enteropathy
(Marsh I-II), 46 CD
(Marsh III)
110 HCs (age and
gender matched) GFD for 1 y
Changes in depression score BA a
GFD (sub-score of PGWB)
3—EmA, tTG
4—Vh/CrD
Kurppa et al.
(2014) [53]
Finland
Multicentre
DB, CO RCT
40 asymptomatic
EmA-positive adults
(CD excluded)
NA
2 arms; participants
randomised to a GFD or
gluten-containing diet for
1 y then cross-over
Difference in mean depression
score between gluten and GFD
groups at 1 y (sub-score of
PGWB)
2—NI on who conducted
3—EmA, tTG
4—Vh/CrD
Deviations from protocol:
No-one in GFD group
willing to restart
gluten-containing diet so
only data from 1 y
FU used
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Table 1. Cont.
Author (Year) Country ofOrigin/Study Design Participants Healthy Controls Interventions Outcomes
Method of Measuring
Adherence * Notes
Nachman et al.
(2009) [58]
Argentina
Single centre
BA comparison/time-
interrupted study
84 newly diagnosed
biopsy-proven CD
patients; 62 classical, 14
atypical and 8
asymptomatic
70 HCs recruited from
hospital staff members
(age and gender
matched)
GFD for 1 y
At baseline, 3, 6, 9 and 12 mo:
Changes in depression score BA a
GFD (BDI)
Changes in no. patients positive
for depression BA a GFD (BDI
score ≥ 18)
Subgroup analysis: Compliant vs.
noncompliant
Opinion of physician in
charge, based on:
1—self-rated questionnaire
2—“meticulous enquiry by an
experienced dietician”
3—tTG, DGP, EmA, AGA
4—Vh/CrD
5—4 day (self-reported)
Nachman et al.
(2010) [57]
Argentina
Single centre
BA comparison/FU
from Nachman et al.
(2009)
53 CD patients; 37
classical and 16
atypical/asymptomatic
70 HCs recruited from
hospital staff members
(age and gender
matched) (same as
Nachman et al. (2009))
GFD for 4 y
At baseline, 1 y and 4 y:
Changes in depression score BA a
GFD (BDI)
Changes in no. patients positive
for depression BA a GFD (BDI
score ≥ 18)
Subgroup analysis: Compliant vs.
noncompliant
Opinion of physician in
charge, based on:
1—self-rated questionnaire
2—“meticulous enquiry by an
experienced dietician”
3—tTG, DGP, EmA, AGA
4—Vh/CrD
5—4 day (self-reported)
Peters et al. (2014)
[42]
Australia
Single centre
DB, PC, CO RCT
20 IBS patients (CD
excluded by biospy);
recruited from a
preceding study in
which subjects with
self-reported NCGS
were challenged with
diets containing varying
amounts of gluten
(Biesiekierski et al.,
2013)
NA
3 arms; low-FODMAPs +
GFD (3 day baseline period)
followed by 3 day:
(a) gluten (16 g/day)
(b) whey (16 g/day)
(protein control)
(c) placebo
with 3–14 day washout
period in between
Difference in depression scores
following each dietary challenge
(sub-score of STPI)
1—validated
5—3 day (self-reported)
6—unused/additional food
counted
Peter R. Gibson has
published two books on a
diet for IBS. This study
was supported by George
Weston Foods as part of a
partnership in an
Australian Research
Council Linkage Project
and the National Health
and Medical Research
Council (NHMRC) of
Australia.
Simsek et al. (2015)
[11]
Turkey
Single centre
BA comparison
24 newly diagnosed
biopsy-proven
paediatric CD patients;
age limit 9–16 y
25 HCs recruited from
same centre;
EmA-negative
GFD for 6–20 mo
Changes in depression score BA a
GFD (CDI)
Subgroup analysis: Compliant vs.
noncompliant
3—EmA, tTG
Ukkola et al.
(2011) [61]
Finland
Nationwide
BA comparison
698 newly diagnosed
(within 1 y)
biopsy-proven CD
patients; 490 classical, 62
atypical and 146
screen-detected
110 HCs (age and
gender matched) GFD for 1 y
Changes in depression score BA a
GFD (subscore of PGWB)
1—unvalidated FU question
(“strict diet” or “dietary
lapses”)
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Table 1. Cont.
Author (Year) Country ofOrigin/Study Design Participants Healthy Controls Interventions Outcomes
Method of Measuring
Adherence * Notes
Vilppula et al.
(2011) [62]
Finland
Nationwide
BA comparison
32 screen-detected
biopsy-proven CD
patients; age > 50 y
110 HCs recruited from
neighbourhoods of CD
patients (age and gender
matched)
GFD for 1–2 y Changes in depression score BA aGFD (subscore of PGWB)
2—with dietician
3—tTG, EmA
4—Vh/CrD
(“Diet considered strict when
there were no signs of dietary
transgressions upon the
interview. Occasional GFD
defined as a gluten intake
occurring less often than once
in the month.”)
NOTE: Studies in alphabetical order. Abbreviations: RCT, randomised controlled trial; BA, before-after; DB, double-blind; PC, placebo controlled; CO, cross-over; CD, coeliac disease;
WA, wheat allergy; GFD, gluten-free diet; HC, healthy control; NC, no control group; IBS(-D), irritable bowel syndrome (diarrhoea-predominant); NCGS, non-coeliac gluten sensitivity;
y, year; mo, month; wk, week; FU, follow-up; M-SDS, modified Zung Self-reported Depression Scale; HADS, Hospital Anxiety and Depression Scale; HDRS, Hamilton Depression
Rating Scale; SCID-I, Structured Clinical Interview for DSM-IV Axis I Disorders; CCEI, Crown-Crisp Experiential Index; PGWB, Psychological General Well-Being Index; BDI, Beck
Depression Inventory; STPI, State-Trait Personality Inventory; CDI, Children’s Depression Inventory; AGA, Anti-gliadin antibodies; EmA, anti-endomysial antibodies; tTG, Anti-tissue
transglutaminase antibodies; Vh/CrD, villous height:crypt depth ratio; DGP, Deamidated Gliadin Peptide; NI, no information; NA, not applicable. * 1, Self-rated questionnaire; 2, Interview;
3, Serology; 4, Histology; 5, Food diary/record; 6, Other.
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3.4. Data and Analyses
A summary of our findings are presented in Tables S9–S12 in Supplementary File 5.
3.4.1. A GFD vs. A Gluten-Containing Diet
3.4.1.1. Difference in Mean Depression Scores
One RCT compared a GFD to a normal gluten-containing diet in a two-arm study [53] and ten
reports of nine single-arm before-after studies compared depression scores for participants at baseline
(on a gluten-containing diet) and after following a GFD. However, two studies were not eligible for
meta-analysis [59,65] and one study [57] was a follow-up of the same sample from another study [58].
Hence, eight studies with a total of 953 participants were included in meta-analysis. We found that a
GFD significantly reduced depressive symptoms in 953 participants overall (SMD −0.37, 95% CI −0.55
to −0.20; p < 0.0001) (Figure 3A). There was low-medium heterogeneity between the studies overall
(I2 = 38%), but zero heterogeneity between the non-randomised studies and RCTs. Subgroup analyses
(Figure S1, Supplementary File 6) revealed no difference in effect between those with and without
diagnosed CD (p = 0.73) or between those HLA-DQ2/8-positive and HLA-DQ2/8-negative (p = 0.49).
Conversely, there was a significant difference in effect between those with classical, atypical and silent
CD (p = 0.003) with high heterogeneity between subgroups (I2 = 82.5%) (Figure 3B); while classical
CD patients exhibited a significant effect (SMD −0.65, 95% CI −0.96 to −0.34; p < 0.0001), the effect
for silent CD patients was nonsignificant (SMD −0.06, 95% CI −0.38 to 0.26; p = 0.71) and one study
reported a significant effect for atypical CD patients.
Of the studies not eligible for meta-analysis, one reported non-normally distributed data as
medians and IQRs as opposed to means and SDs [59] and one only reported mean scores for patients
positive for depression rather than all participants [65]. One study included in meta-analysis did not
report SDs for the PGWB subcategories [61], so SDs for the mean depression values were estimated
using methods described in the Cochrane Handbook [45] and 95% CI values imputed from an
ad-hoc analysis of the same population sample [66]. Only data for the classical CD patients from
Nachman et al. [58] were used because this was the only data reported for the modified BDI removing
questions to avoid bias due to illness. Moreover, only scores for adherent participants (n = 7) were
used from Simsek et al. [11] as noncompliance was high with 17/24 participants (71%) found not
to follow a strict GFD. Finally, one study providing data for a second follow-up at four years [57]
suggests an insignificant trend towards worsening depressive symptoms relative to one year (p = 0.39),
which remained significant relative to baseline (p < 0.0001) (Figure S2, Supplementary File 6).
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Figure 3. Forest plot demonstrating the difference in mean depression scores between following a GFD
and a gluten-containing diet for (A) all studies (1 RCT comparing two intervention groups and seven
BA studies comparing participant scores at baseline) and (B) subgroup analysis based on symptoms
(classical, atypical and asymptomatic). CI, confidence interval; df, degrees of freedom; GFD, gluten-free
diet; GCD, gluten-containing diet; I2, heterogeneity; IV, inversed variance; Random, random effects
model; SD, standard deviation; Std., standardised; total, number of patients.
3.4.1.2. Change in Number of Participants Positive for Depression
Four reports of three studies compared the number of participants positive for depression at
baseline and after following a GFD. Three were included in meta-analysis (Figure 4). For 110 classical
CD patients, there was a reduction of 31% of patients positive for depression after following a GFD (RD
−0.31, 95% CI −0.52 to −0.10; p = 0.003). All the included data is for classical CD patients following
a GFD for one year; no studies reported this outcome for non-CD patients. We found a significant
difference in effect between the studies reporting results from modified and unmodified questionnaires,
with a significant effect seen for the unmodified questionnaires and a nonsignificant effect in studies
using an unmodified questionnaire.
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3.4.2. Gluten Challenge vs. Placebo (GFD)
Two RCTs compared the mean depression scores of subjects during the gluten and placebo
challenge periods and were included in meta-analysis [42,56] (Figure 5). We found a trend towards
worsened depressive symptoms during the gluten challenge period compared to placebo, although
this did not reach significance (SMD 0.21, 95% CI −0.58 to 0.15; p = 0.25). Heterogeneity was low
(I2 = 19%). Both used a cross-over trial design with participants acting as their own controls and both
adequately described blinding of participants and researchers. Moreover, both used a per-protocol
(PP) approach in their analyses. Depression scores were derived from a graph by optical plot reading
using WebPlotDigitizer [52].Nutrients 2018, 10, x FOR PEER REVIEW  14 of 25 
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Figure 5. Forest plot demonstrating the difference in participant depression scores between gluten and
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3.4.3. Compliant vs. Noncompliant Participants
Three publications of two studies reported depression scores separately for CD patients
compliant and noncompliant to the GFD; no studies reported separate data for these subgroups
in non-CD patients. However, two of the three studies used the same sample at different follow-up
timepoints [57,58]. Moreover, as there is considerable variation in results and inconsistency in the
direction of effect, no meta-analysis was conducted (Figure 6). Firstly, Nachman et al. [58] found a
nonsignificant difference in mean depression scores bet een 59 co pliant ( −7.9, 95% CI 4.8 to 11.0)
and 25 no compliant patients (M −6.3, 95 I 3.6 to 9.5) at year one, although there was a slightly
lower sev rity of depressive symptoms in the li t subgroup. Neverth less, they reported
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a significantly higher severity of depression in the noncompliant subjects after four years on a GFD
(p = 0.04), with 27 compliant and 26 noncompliant CD patients having mean scores of 5.8 (95% CI
2.1 to 9.5) and 11.3 (95% CI 7.6 to 15.0), respectively [57]. Conversely, when comparing the number
of patients positive for depression (Figure S3, Supplementary File 6), they consistently reported a
nonsignificant trend towards a lower number of depressed patients in the compliant group, with
no difference between the proportion of depressed patients at one year and four year follow-ups
(p = 0.86; I2 = 0%). On the contrary, Simsek et al. [11] found the severity of depressive symptoms to be
significantly higher in noncompliant, compared to compliant, CD children after only one year on a
GFD (p = 0.005), with seven compliant patients and 17 noncompliant patients achieving mean CDI
scores of 4.75 (SD 3.3) and 12.33 (SD 5.8), respectively.
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Figure 6. Mean depression scores in compliant vs. noncompliant CD adults at one year, CD children at
one year, and CD adults at four years after following a GFD.
3.4.4. GFD-Treated Patients vs. Healthy Controls
3.4.4.1. Difference in Mean Depression Scores
Five publications reporting on four studies included an eligible healthy control group, of which
four were included in meta-analysis (Figure 7A). As Nachman et al. [57,58] used the same sample
and healthy controls, the results for the four year follow-up [57] were reported separately. Overall,
we found no difference between the depressive outcome scores between 868 GFD-treated patients
and 400 healthy controls at one year follow-up (SMD 0.01, 95% CI −0.18 to 0.20, p = 0.94) and zero
heterogeneity between the studies (I2 = 0%). Similarly, there was no significant difference at the four
year follow-up between 27 strictly adherent patients and 70 healthy controls (SMD −0.08, 95% CI
−0.52 to 0.36, p = 0.72). Two studies with a healthy control group were not eligible for meta-analysis;
Simsek et al. [11] reported depressive outcome data for their healthy controls as medians and IQRs,
but similarly reported an insignificant difference between patients and controls, while Collin et al. [64]
did not demographically match patients and healthy controls, hence we have not reported their data.
3.4.4.2. Difference in Number Participants Positive for Depression
Three studies [57,58,65] reported the number of GFD-treated participants and healthy controls
positive for depression, of which two were meta-analysed and data from Nachman et al. [57] were
reported as separately (Figure 7B). Only data from patients strictly adherent to the GFD were included.
We found a trend towards an increased prevalence of depression in GFD-treated patients compared
to healthy controls at one year (RD 0.21, 95% CI −0.16 to 0.58; p = 0.26) and four years (RD 0.10, 95%
CI −0.02 to 0.22; p = 0.12), although these were nonsignificant. There was no significant difference
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between the results at one year and four years (p = 0.56), and heterogeneity was zero between all
studies and subgroups.
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and (B) the difference in the no. treated patients and healthy controls positive for depression at one
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3.5. Sensitivity Analyses
Various sensitivity analyses were untaken to ensure significant differences were not as a result of
arbitrary decisions throughout the study process (Figures S4–S6 and Tables S13–S14, Supplementary
File 7). Firstly, no significant differences in meta-analysis results were found when interchanging
random-effects for fixed-effects, or risk difference for odds ratio and risk ratio, for the majority of
analyses (Tables S13 and S14). However, there was a difference in the final results for analysis
Section 3.4.4.2. at one year, which became significant when using fixed-effects, s opposed to
random-effects, and odds ratio or risk ratio, s opposed to risk differenc . Secondly, removing
studies at an unclear/high risk of detection bias, leaving only those at low risk, did not produce
substantially different results for any applica le comparison (Figure S4). Thirdly, while removing
data from Nachman t al. [58] fr m our meta-analyses did not si nificantly alter the results, overall
heterogeneity was reduced from I2 = 38% to I2 = 0% for the main analysis (Figure S5) and from I2 = 52%
to I2 = 13% for the CD subgroup. On the other hand, there was no difference in results or heterogeneity
between using outcome data from Nachman et al. for classical CD patients from the modified BDI and
the unmodified BDI [58], or all CD patient subgroups from the unmodified BDI [57] (Figure S6). Finally,
the results from a potential conference abstract for a cross-over RCT [67], excluded from our study
due to the lack of a published final article, could not be included in a sensitivity analysis as only the
Nutrients 2018, 10, 1708 16 of 24
mean change in the STPI state depression sub-score was reported between gluten and placebo groups
(mean change 0.69, 95% CI −2.15 to 3.53, p = 0.61). Nevertheless, these results for NCGS patients are in
agreement with our meta-analysis in Section 3.4.2.
3.6. Publication Bias
Inspection from the funnel plot that arose from our main analysis (Figure 8) suggests the presence
of publication bias due to location biases [68], with published studies from Finland less likely to find
to find a large effect from a GFD on reducing depressive symptom scores relative to published studies
from other countries.
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4. Discussion
Our systematic review involved a total of 13 studies and 1139 patients, with meta-analysis on an
eligible sample of 933 patients from non-randomised studies and 99 patients fro RCTs, as well as
180 healthy controls. Although we generally found a low level of heterogeneity, a limitation of our
review was the small number of studies available for subgroup analyses that limited our ability to
investigate any heterogeneity. Moreover, despite the fact that we contacted authors for missing data,
no additional data was retrieved. This was either because: The data was no longer available; authors
had retired or moved to another area of research; or a lack of response. Nevertheless, we adhered to
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [69]
guidelines wherever possible (see PRISMA checklist, Table S15 in Supplementary File 8) and assessed
the quality of the individual studies using tools developed and recommended by the Cochrane
Collaboration for both the RCTs and non-randomised studies. Moreover, we applied the GRADE
process [48] to assess the certainty of our conclusions and recommendations based on the evidence
across the studies for each outcome.
A further strength of our systematic review was our comprehensive search strategy, which we
piloted and tailored to numerous databases, and strict application of inclusion and exclusion criteria.
Therefore, we are relatively certain that all relevant studies have been included in our review. Although
diagnosed conditions or disorders were not an exclusion criteria for our study, only studies on
populations with CD, IBS or NCGS were identified through our searches; no other gluten-related
disorder, such as dermatitis herpetiformis or gluten ataxia, nor any other condition, such as major
depressive disorder, were identified. Moreover, our searches only identified studies assessing
depression, or depression as a subcategory of quality of life; no studies were found that assessed
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other determinants of mood or mood disorders. We conducted further, broader searches for other
mood disorders as a sensitivity analysis in attempts to find studies we may have missed in our search
strategy, but identified no further relevant studies. As we found no studies that attempted a GFD
intervention on a sample of patients with depression, despite evidence for significantly higher levels of
gluten-related antibodies in patients with major depressive disorder [19], this would be an interesting
topic for future studies to address in order to help assess the directionality of the relationship between
depression and gluten.
Our first objective was to establish whether a relationship exists between mood and gluten in
those with and without gluten-related disorders. We found that a long-term GFD may significantly
reduce and normalise the severity of depressive symptoms for subjects with CD, IBS and NCGS,
with a medium-large effect for both symptomatic and atypical CD patients, but no effect for
asymptomatic/silent cases [70]. However, the criteria for what constitutes silent CD remains uncertain;
although neuropsychiatric disorders are likely to be included in the definition of atypical CD [71],
there are a variety of pathophysiological differences underlying the clinical spectrum of depressive
disorders [72]. Hence, it is uncertain whether those with depression, but no other symptoms, at baseline
would be classified as having atypical or silent CD. Moreover, one of our included studies found that the
significant improvement in depressive symptoms for the atypical/silent combined subgroup was no
longer significant when the questionnaire was modified to remove questions based on gastrointestinal
symptoms [58]. Conversely, another one of our included studies reported that all asymptomatic CD
participants randomised to the GFD group for the first year of the study refused to crossover to a
follow a gluten-containing diet again, due to a fear of worsening symptoms [53], suggesting that even
subjects who did not report any symptoms at baseline experienced improvements after following a
GFD. Hence, although we established an overall effect, is it difficult to draw many conclusions based
on symptom classification at this time.
Further to this, we assessed the impact of the level of adherence to a GFD on mood symptom
severity. Interestingly, we found a significant difference in mean depression scores in favour of strict
compliance for CD children after one year, whereas the difference for CD adults was nonsignificant
at the same timepoint. This, nevertheless, became significant in favour of compliance at the four
year follow-up. Previous systematic reviews and meta-analyses have consistently found a moderate
association between poorer GFD adherence and worsened depressive symptoms [35,73], though with
high heterogeneity between the studies. However, our nonsignificant finding for adults after the first
year does not support this relationship described by others. On one hand, a standardised method for
measuring adherence to the GFD does not yet exist, and hence there were differences in the methods
utilised by each studies. Alternatively, recent cross-sectional studies suggest that hypervigilance to a
GFD, associated with greater knowledge, was significantly associated with reduced quality of life [44],
and that those with worse economic status were at an increased risk of lower quality of life while
following a GFD [74]. Conversely, the presence of depression has been suggested to weaken the
correlation between GFD adherence and symptoms [43], implying that symptoms may be driven by
factors other than gluten exposure. To summarise, further studies with standardised measurements of
adherence are required before definitive conclusions may be drawn on the effects of gluten-free dietary
adherence on the severity of depressive symptoms.
On the other hand, we found the proportion of participants testing positive for depression
tended to be higher in GFD-treated patients compared to healthy controls at both one and four years,
which was unaffected by the level of compliance. In line with this, previous studies suggest that up
to 30% of CD patients show persistent enteropathy after one year on a GFD [75], potentially due to
consuming trace amounts of gluten via cross-contamination [76,77]. Despite this, recent RCTs suggest
that a low-FODMAPs diet can further reduce the severity of depressive symptoms in those with
NCGS [29] and CD [78] already on a GFD, although further research is needed in this area. In addition,
while it has been suggested that altered gut microbiota may contribute to the psychiatric effects of a
GFD [29,79,80], results should not be extrapolated from one population to another, due to the highly
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individualised pattern of gut microbial composition [81]. In any case, future studies should be mindful
of the shortcomings of only considering mean scores of the sample as a whole, and closer attention
should be paid to patients who may be unresponsive to a GFD in research and practice.
In terms of the short-term effects for gluten on mood, the trend towards increased severity
of depressive symptoms in NCGS patients after only a few days of a blinded gluten challenge
further reinforces our findings that the ingestion of gluten plays a role in the presence of depressive
symptoms—even in those without mucosal gut damage. Although one of our included studies
reported no concurrent differences in gastrointestinal symptom severity between gluten, whey and
placebo challenges [42], other clinical trials on non-CD participants report a significant increase in
physical symptoms when challenging with foods containing wheat [82] and fructans [83]. Additionally,
despite the fact that another RCT found no gluten-specific gastrointestinal symptoms when challenging
NCGS patients already on a low-FODMAPs diet, all patients returned to a GFD at the end of the trial
as they subjectively reported “feeling better” [28]. However, the weaknesses of this study have been
discussed in a previous paper [84]; while the sample is unlikely to be representative of the NCGS
population, the crossover design could have also produced an anticipatory nocebo response [85].
Nonetheless, a proposed mechanism requiring further investigation is that FODMAPs predominantly
trigger GI symptoms whereas gluten is a trigger for neurological and psychiatric symptoms by having
direct effects on the brain [86].
Unfortunately, the overall quality of the evidence base was poor and confounding factors were
problematic. Firstly, while a few studies stated subject antidepressant use as an exclusion criteria,
other studies did not consider this. Secondly, seasonal affective disorder (SAD), a type of depression
with a seasonal pattern, may overlap with other depressive disorders [87], but was not considered or
controlled for in any of the studies. Although the majority of the non-randomised studies planned the
follow-up to be one year after the start of the GFD, this timespan varied between clients, as well as
between studies and none specified the time of year. Moreover, some of the questionnaires utilised,
namely the SDS, HDRS and BDI, contained questions related to gastro-intestinal symptoms and eating
habits, which are likely to introduce bias due to physical illness. Finally, our sample is dominated by
Finnish participants (75.8%), with only 9.4% participants from Italy and 3.6% from the UK, significantly
reducing the applicability of our findings; a GFD may be easier to follow in Finland as there is good
knowledge of CD and easy availability of gluten-free products [88], which may lead to a lower risk of
depression, due to isolation and other issues associated with following a GFD.
Nonetheless, we set out to determine implications for future research, as well as implementation
of GFDs in practice. Firstly, our included studies varied in their criteria for CD diagnosis; whereas one
study relied on EmA-positivity [53], another used biopsy [61] as their criteria for inclusion of silent
CD patients. Moreover, broad subcategories, such as ‘atypical’, were problematic when attempting to
assess specific atypical symptoms, such as depression. Hence, specific standardised criteria for the
classification of the different subtypes of CD, as well as other gluten-sensitive disorders, should be
developed to aid further research in terms of comparability, as well as identification and suitable
treatment of those with CD. Secondly, our finding that the proportion of adults strictly adherent to
the GFD decreased significantly over time is supported by a large recent meta-analysis [35], and is
likely related to the amount of support received by patients. For instance, a RCT found that six months
of psychological counselling improved GFD adherence and reduced depression in CD patients with
depression at baseline [89]. While no studies exist that support or repute our findings that a lower
proportion of children achieved strict adherence than adults, practical tools have been shown to
promote self-management, dietary adherence and well-being in children and adolescents with CD [90].
Hence, the development of both standardised measurement methods and tools to promote dietary
adherence would be useful for future research, as well as patient management. Moreover, a balance
between dietary adherence and well-being appears important for those following a GFD, with careful
consideration of the level of support available for specific populations in maintaining a GFD diet
over time.
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5. Conclusions
Our study confirms that gluten elimination may represent an effective treatment strategy for
mood disorders in individuals with gluten-related disorders, while highlighting specific considerations
for future research and implications for practice. Firstly, standardisation of methods to measure
dietary adherence and mood symptoms with no bias, due to physical illness would greatly increase
the validity and comparability of future research. Secondly, future studies focusing on gluten
and mood in participants without a gut-related disorder, for example, in a population sample
with depression, would contribute to the evidence necessary to determine the directionality of the
relationship. Nevertheless, authors should be mindful of the shortcomings of only considering mean
scores of a sample, with potentially GFD-resistant participants requiring closer attention. In practice,
implementation of a gluten-contamination elimination diet, such as that detailed by Hollon et al. [76],
in which processed foods are eliminated, could prove beneficial for some individuals. Thirdly,
standardisation of the classification for the subtypes of CD, as well as other gluten-sensitive disorders,
should be developed to aid further research in terms of comparability, as well as identification
and suitable treatment of those with CD. Finally, the level of support available to help a patient
in maintaining a GFD diet over time should be carefully considered when recommending a GFD
in practice.
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